ArticleCancer medicine2025
Habitat Radiomics Predict HPV Status in Oropharyngeal Cancer.
Article in Cancer medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Multi-regional radiomics based on planning CT and information complementarity between GTVp and GTVn: an explainable model for predicting 5-year recurrence risk in HPV-positive oropharyngeal cancer.Radiation oncology (London, England) · 2026Article
- Review
- Preoperative CT-Based Habitat Radiomics Classifiers Predict Recurrence in Non-Small Cell Lung Cancer.medRxiv : the preprint server for health sciences · 2026Article
- Habitat Radiomics Predict HPV Status in Oropharyngeal Cancer.Cancer medicine · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
objectiveThis study developed a habitat-based radiomics classifier from CT images to predict HPV status in oropharyngeal cancer (OPC).
methodsWe analyzed pretreatment CT scans from 192 OPC patients. Tumor habitats were generated using a two-level unsupervised clustering approach, and radiomics features were calculated from both intratumoral and habitat-defined subregions. HPV ground truth was based on p16 IHC, and the ROSE algorithm was used to address class imbalance (85% HPV-positive). LASSO regression was used for feature selection. We developed and compared three separate models for statistical performance to predict HPV status: habitat radiomics classifier, intratumoral radiomics classifier, and combined radiomics classifier (habitats and intratumoral). Classifier performance was assessed using area under the receiver operating characteristic curve (AUCROC), and SHAP (SHapley Additive Explanations) was utilized to interpret features contributing to classifier predictions. Kaplan-Meier analysis was conducted to compare survival outcomes of HPV ground truth versus the radiomics classifier.
resultsThe habitat radiomics classifier significantly outperformed the intratumoral radiomics classifier, achieving AUCs of 0.970 (95% CI, 0.942-0.997) in the training cohort and 0.937 (95% CI, 0.843-1.00) in the test cohort. The combined radiomics classifier did not significantly improve performance. SHAP revealed that radiomic features of compact/spherical shape and uniform texture were associated with HPV-positive tumors, reflecting lower morphologic and textural heterogeneity than HPV-negative tumors. For the survival analysis, the HPV habitat radiomics classifier is indistinguishable from HPV ground truth in predicting overall survival (p = 0.52 for HPV-negative ground truth vs. HPV-negative classifier; p = 0.75 for HPV-positive ground truth vs. HPV-positive classifier).
conclusionThe habitat radiomics classifier provides an imaging-based algorithm to predict HPV status in OPC by capturing spatial patterns of tumor heterogeneity that reflect biological differences between HPV-positive and HPV-negative tumors. This approach demonstrated strong performance, with additional support from SHAP-based interpretability and Kaplan-Meier survival analysis suggesting its potential clinical relevance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.